DDInter1124 DDInter1676
Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Maprotiline {u} (Compound) resembles {v} (Compound) Protriptyline
Maprotiline {u} (Compound) resembles {v} (Compound) Demexiptiline
Maprotiline {u} (Compound) binds {v} (Gene) ABCB1
Maprotiline {u} (Compound) upregulates {v} (Gene) UBE2L6
Maprotiline {u} (Compound) palliates {v} (Disease) panic disorder
Maprotiline {u} (Compound) downregulates {v} (Gene) CCNA2
Maprotiline {u} (Compound) causes {v} (Side Effect) Angiopathy
Maprotiline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Maprotiline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ephedrine
Maprotiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Maprotiline (Compound) resembles Protriptyline (Compound)
Maprotiline (Compound) resembles Demexiptiline (Compound)
Maprotiline (Compound) binds ABCB1 (Gene)
Maprotiline (Compound) upregulates UBE2L6 (Gene)
Maprotiline (Compound) palliates panic disorder (Disease)
Maprotiline (Compound) downregulates CCNA2 (Gene)
Maprotiline (Compound) causes Angiopathy (Side Effect)
Maprotiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Maprotiline may cause a minor interaction that can limit clinical effects when taken with Ephedrine
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib